WO2001026642A3 - Procedes et compositions pour le traitement de troubles de comportement neurologique - Google Patents

Procedes et compositions pour le traitement de troubles de comportement neurologique Download PDF

Info

Publication number
WO2001026642A3
WO2001026642A3 PCT/US2000/027894 US0027894W WO0126642A3 WO 2001026642 A3 WO2001026642 A3 WO 2001026642A3 US 0027894 W US0027894 W US 0027894W WO 0126642 A3 WO0126642 A3 WO 0126642A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating
compositions
disorders
diagnosis
Prior art date
Application number
PCT/US2000/027894
Other languages
English (en)
Other versions
WO2001026642A2 (fr
Inventor
Joyce Corinne Bechthold
Thomas Duff Lilly
Original Assignee
Joyce Corinne Bechthold
Thomas Duff Lilly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joyce Corinne Bechthold, Thomas Duff Lilly filed Critical Joyce Corinne Bechthold
Priority to AU80038/00A priority Critical patent/AU8003800A/en
Publication of WO2001026642A2 publication Critical patent/WO2001026642A2/fr
Publication of WO2001026642A3 publication Critical patent/WO2001026642A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour le traitement de troubles de comportement neurologique, par la restauration de la fonction normale de transport et métabolique des neurotransmetteurs, des récepteurs. La première étape du traitement consiste à administrer en intraveineuse une composition destinée à traiter les symptômes du patient. La prochaine étape consiste à lui administrer un support oral. L'invention concerne également des compositions pour le traitement en intraveineuse de certains types de troubles neurobiologiques et des méthodes de diagnostic, comprenant des test spécialisés et le diagnostic préalable des conditions neurologiques sous-jacentes, la vaccination, et des méthodes d'éducation et de soutien psychologiques disponibles à distance sur l'Internet ou par courrier.
PCT/US2000/027894 1999-10-08 2000-10-06 Procedes et compositions pour le traitement de troubles de comportement neurologique WO2001026642A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU80038/00A AU8003800A (en) 1999-10-08 2000-10-06 Methods and compositions for treating neurobehavioral disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15860499P 1999-10-08 1999-10-08
US60/158,604 1999-10-08
US16404999P 1999-11-08 1999-11-08
US60/164,049 1999-11-08
US16606899P 1999-11-17 1999-11-17
US60/166,068 1999-11-17
US20104300P 2000-05-01 2000-05-01
US60/201,043 2000-05-01

Publications (2)

Publication Number Publication Date
WO2001026642A2 WO2001026642A2 (fr) 2001-04-19
WO2001026642A3 true WO2001026642A3 (fr) 2002-05-10

Family

ID=27496343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027894 WO2001026642A2 (fr) 1999-10-08 2000-10-06 Procedes et compositions pour le traitement de troubles de comportement neurologique

Country Status (2)

Country Link
AU (1) AU8003800A (fr)
WO (1) WO2001026642A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6423349B1 (en) * 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery
WO2002043507A2 (fr) 2000-11-30 2002-06-06 The Health Research Institute Complements nutritifs et procedes de traitement de l'autisme et de prevention de l'apparition de l'autisme
CN1537009A (zh) 2001-04-25 2004-10-13 �ư������������޹�˾ 一种用于治疗或者预防个体功能性维生素b12缺陷的方法以及在该方法中使用的药物组合物
DE10149108A1 (de) * 2001-10-05 2003-04-30 Degussa Bioactives Deutschland Verwendung von Phosphatidylserin zur Behandlung des Aufmerksamkeits-Defizit-Syndroms (ADHS)
EP1302196A1 (fr) * 2001-10-16 2003-04-16 Habinger, René, Ing. Mag. Dentifrice pour promouvoir l'intelligence
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
AU2003299311A1 (en) * 2002-12-18 2004-07-09 University Of Zurich Treatment of neuro-psychiatric disorders
US7115285B2 (en) * 2003-03-14 2006-10-03 Eurark, Llc Composition and method for appetite and craving suppression and mood enhancement
CA2593563A1 (fr) * 2005-01-05 2006-07-13 Magd Ahmed Kotb Abdalla Synthese de taurine, production et utilisation de celle-ci comme medicament
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
AU2009259887A1 (en) * 2008-06-21 2009-12-23 B. William Downs DNA-directed customization of analgesic compounds as a therapeutic modality
WO2011041451A2 (fr) * 2009-09-30 2011-04-07 Harlan Clayton Bieley Arrêter de fumer avec maintien du poids corporel et complément nutritionnel
US20120244213A1 (en) * 2009-12-17 2012-09-27 Liora Emanuel Methods for the treatment of speech impediments
ES2375391B1 (es) * 2010-08-17 2013-07-31 Vitae Natural Nutrition, S.L. Composición de complemento nutricional.
CN102526103B (zh) * 2010-12-07 2013-11-13 西藏海思科药业集团股份有限公司 一种多种微量元素注射液药物组合物及其制备方法
US20130090356A1 (en) * 2011-06-24 2013-04-11 Jon D. Kaiser Compositions and methods for treatment of neuropsychological deficits
US9040082B2 (en) * 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
WO2014026161A1 (fr) * 2012-08-10 2014-02-13 Aquavit Pharmaceuticals, Inc. Compositions de supplément de vitamines pour une injection
US10980865B2 (en) 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
EP2737809A1 (fr) * 2012-12-03 2014-06-04 MüMed Boisson contenant des acides aminés, appropriée à une utilisation dans la prophylaxie et le traitement de perturbations physiques
CN104055759B (zh) * 2014-06-16 2016-08-31 重庆工商大学 一种药物组合物及其应用
SI3242676T1 (sl) 2015-01-07 2024-02-29 Tonix Pharma Limited Formulacije oksitocina, ki vsebujejo magnezij in načini uporabe
US20160331709A1 (en) * 2015-05-13 2016-11-17 Wow Llc??? Balancing an Unbalanced Sympathetic Nervous System
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
KR101840003B1 (ko) 2017-02-07 2018-03-19 한국과학기술연구원 행위 중독의 진단용 조성물, 키트 및 이를 이용한 행위 중독의 진단을 위한 콜레시스토키닌의 검출 방법
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
IL296055A (en) 2017-08-14 2022-10-01 Axcella Health Inc Amino acid compounds for the treatment of liver disease
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
RU2709501C1 (ru) * 2019-10-15 2019-12-18 Виктор Александрович Сисев Фармацевтическая композиция для парентерального капельного введения
US20230037437A1 (en) * 2019-12-18 2023-02-09 Unibiolabs Internacional S.A De C.V Formulations for use in the treatment of different types of addictions and dependence on addictive substances
BR112022017433A2 (pt) * 2020-03-11 2022-10-18 Purdue Pharma Lp Composições e métodos para distribuição de naloxona
DE102020130273A1 (de) 2020-11-17 2022-05-19 Vivant Biotechnology Gmbh Wirkstoff-Zusammensetzung
DE102020008090A1 (de) 2020-11-17 2022-05-19 Vivant Biotechnology Gmbh Wirkstoff-Zusammensetzung
WO2023247760A1 (fr) * 2022-06-24 2023-12-28 Xellia Pharmaceuticals Aps Formulation d'oxytocine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6434917A (en) * 1987-07-31 1989-02-06 Snow Brand Milk Products Co Ltd Sterilized transintestinal liquid nutrient kit composed of plural liquids
EP0625312A1 (fr) * 1992-11-10 1994-11-23 Otsuka Pharmaceutical Co., Ltd. Compostion d'aliment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6434917A (en) * 1987-07-31 1989-02-06 Snow Brand Milk Products Co Ltd Sterilized transintestinal liquid nutrient kit composed of plural liquids
EP0625312A1 (fr) * 1992-11-10 1994-11-23 Otsuka Pharmaceutical Co., Ltd. Compostion d'aliment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI 1997 Derwent World Patents Index; AN 396363, XP002171900, JKZH: "Liquefied sterilisation enteral hyper-alimentation drug for improved absorption-comprises aqueous solution comprising nitrogen source comprising aminoacid and/or low molecular peptide, minerals and vitamin C, and emulsification liquid" *

Also Published As

Publication number Publication date
AU8003800A (en) 2001-04-23
WO2001026642A2 (fr) 2001-04-19

Similar Documents

Publication Publication Date Title
WO2001026642A3 (fr) Procedes et compositions pour le traitement de troubles de comportement neurologique
EP1140170A4 (fr) Nouveaux agents et methodes pour le traitement et le diagnostic de troubles oculaires
MXPA03010843A (es) Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
Sanberg et al. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome
WO2004073614A3 (fr) Polytherapie servant au traitement de troubles immuno-inflammatoires
Chadwick et al. Manipulation of brain serotonin in the treatment of myoclonus
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
NO962130L (no) Synergistisk behandling av Parkinsons sykdom
WO2005020972A3 (fr) Polytherapie pour le traitement de troubles neovasculaires oculaires
WO2004043341A3 (fr) Traitement pour choc hémorragique
WO1999064059A3 (fr) Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques
UA86344C2 (ru) Способ лечения сосудистых заболеваний
SG170119A1 (en) Nutritional composition comprising indigestible oligosaccharides
WO2005037832A3 (fr) Compositions pharmaceutiques et methodes destinees au soulagement de la douleur et au traitement de troubles du systeme nerveux central
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
WO2005048927A3 (fr) Procedes et reactifs pour le traitement de troubles inflammatoires
Abgrall et al. Localized neurological necrotizing vasculitides. Three cases with isolated mononeuritis multiplex.
Aisen et al. A double-blind placebo-controlled study of 3, 4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit
WO2005056601A3 (fr) Anticorps humains diriges contre pseudomonas-aeruginosa, derives d'une xenosouris transgenique
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
Léger et al. Diagnosis of motor neuropathy
Prevett et al. Improvement of stiff‐man syndrome with vigabatrin
WO2002005798A3 (fr) Compositions pharmaceutiques et leurs methodes d'utilisation
PFEFFERBAUM et al. Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma
Özön et al. Acute ascending myelitis and encephalopathy after intrathecal cytosine arabinoside and methotrexate in an adolescent boy with acute lymphoblastic leukemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP